Louis J Sheehan 80242

Louis J Sheehan In February, for example, the Food and Drug Administration approved MammaPrint, a test designed to help breast cancer patients. MammaPrint surveys 70 genes in tumor cells, checking whether they’re turned on or off in an individual patient. By reading each patient’s total gene activity profile, doctors can predict whether a tumor is likely to spread and thus whether the patient needs to undergo chemotherapy in addition to surgery. The company behind the test, Agendia, based in the Netherlands, estimates that it will spare 60,000 American women unnecessary chemotherapy each year.